L'estrogel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of L'estrogel

Property Description
Active ingredient Estradiol (17β-estradiol)
Form Transdermal Hydroalcoholic Gel, Metered-Dose Pump
Pharmacological class Estrogen Derivative, Systemic Estrogen
Common use Hormone Replacement Therapy (HRT)
Origin Bioidentical Estrogen

What Type of Medicine is L'estrogel?

L'estrogel is a prescription-only medication classified as an estrogen derivative used for Systemic Estrogen Replacement Therapy. Its fundamental identity is that of a hormone preparation intended to address deficiencies in the body’s endogenous estrogen supply, a need that is clinically recognized in women experiencing hormonal decline. The drug functions as an estrogen receptor agonist, meaning its basic action is binding to and activating hormone receptors throughout the body. This approach provides necessary hormonal support, helping to mitigate the widespread systemic effects associated with significant hormone loss.


Composition, Form, and Origin: Estradiol Transdermal Gel

The sole active ingredient in L'estrogel is estradiol, specifically 17β-estradiol, which is chemically identical to the primary estrogen naturally produced by the human ovary. The medication is formulated as a clear, hydroalcoholic transdermal gel and is distinguished by its metered-dose pump delivery system, ensuring precise product application. This dosage form allows the estradiol to be absorbed through the skin barrier (transdermal route) by passive diffusion, enabling the active component to enter the systemic circulation. The composition includes the bioidentical estradiol active ingredient and a vehicle primarily containing alcohol and purified water, which supports absorption and is often preferred as a non-patch delivery method.


General Purpose: Addressing Estrogen Deficiency

The core general purpose of this therapy is to correct states of estrogen deficiency. By replenishing the body's diminished estradiol supply, the therapy restores hormonal actions in tissues that rely on the hormone for normal function. Research consistently confirms that systemic estrogen therapy is effective for managing symptoms resulting from the lack of natural hormone production. This means the therapy can help stabilize the body's systems that become imbalanced when estrogen levels drop. This replacement strategy is primarily employed to address the systemic physical and vasomotor symptoms that commonly arise following the transition into menopause.

Regulatory References

  1. NIH DailyMed for Estradiol Gel

What side effects are possible with L'estrogel?

Possible Side Effects and Safety Information

The safety profile for estradiol transdermal gel (L'estrogel) is structured by regulatory bodies to describe both common events and serious, documented risks associated with systemic estrogen therapy. This information is derived strictly from official government labeling, organizing adverse reactions by frequency and physiological system.

Officially Documented Serious Risks

Regulatory documents highlight several serious adverse reactions. The use of systemic estrogen-alone therapy is associated with an increased risk of Endometrial Cancer in women with an intact uterus, Stroke, and Deep Vein Thrombosis (DVT). There is also an increased risk of Breast Cancer and Pulmonary Embolism (PE), and a documented increased risk of probable dementia in postmenopausal women aged 65 years and older.

Adverse Reactions Classified by Frequency

Adverse reactions are formally categorized based on incidence observed in official regulatory data, grouped by the affected body system (System Organ Class).

System Organ Class Common Adverse Reactions (Affecting 1 to 10 users in 100)
Reproductive System & Breast Unscheduled vaginal bleeding/spotting, breast pain/tenderness.
Nervous System Headache, dizziness.
Gastrointestinal Nausea, vomiting, abdominal pain, flatulence.
General & Administration Site Application site irritation, peripheral edema, weight changes.

Contextual Safety Patterns

Official labels note specific time-related patterns: irregular bleeding or spotting may occur during the first three to six months of treatment initiation. Furthermore, the risk of Venous Thromboembolism (VTE) is officially stated to be higher during the first year of Hormone Replacement Therapy. The medication is formally contraindicated in individuals with a history of estrogen-dependent cancer, unexplained vaginal bleeding, or active thromboembolic disease.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with L'estrogel primarily results in documented signs of hyperoestrogenism, which is the clinical manifestation of excessive estrogen exposure. Regulatory information from government authorities outlines specific symptoms that may arise in an overexposure scenario, often involving gastrointestinal and hormonal systems.

Documented Overdose Manifestations

Official labeling describes that overdosage may present with:

  • Gastrointestinal effects such as nausea, vomiting, and stomach pain.
  • Reproductive and hormonal signs including abnormal vaginal bleeding and breast tenderness or tension.
  • Central nervous system effects, specifically nervousness and drowsiness.

Required Emergency Actions

It is officially mandated that patients seek immediate medical attention upon any suspicion of overdosage. Patients are explicitly instructed to contact a poison control center or emergency room at once.

Management is restricted to symptomatic and supportive measures, as no specific antidote is known for estradiol overdosage. Regulatory documents note that these signs of hyperoestrogenism are generally expected to disappear once the application of the gel is reduced or discontinued.

Therapeutic Uses of L'estrogel

What L'estrogel Treats: Main Uses and Benefits

The medication is applied in therapeutic situations involving moderate to severe symptoms related to systemic imbalance, particularly vasomotor symptoms and vulvar and vaginal atrophy due to menopause. The systemic estrogen delivery is commonly used to help with managing these conditions presenting with systemic discomfort and corresponds to established therapeutic areas. This therapy may assist with easing symptom clusters that interfere with daily comfort, which can include pronounced hot flashes, excessive night sweats, vaginal dryness, burning, and painful intercourse (dyspareunia).

Therapeutic Scope and Benefit

This medication is also considered relevant for easing the symptoms related to systemic imbalance across skeletal tissue, and is commonly used to help with the prevention of postmenopausal osteoporosis in conditions characterized by a significant risk of fracture, when non-estrogen options are not suitable. It provides supportive relief that helps patients cope more steadily with difficult episodes, such as those occurring during the acute onset of estrogen deficiency following oophorectomy or in cases of premature ovarian insufficiency. This assists with maintaining functional stability and contributes to improved day-to-day comfort.


Quick Fact: Areas of Application for Vasomotor and Urogenital Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use L'estrogel?

The population eligibility for L'estrogel (Estradiol Gel) is strictly defined by government regulatory documents, focusing on absolute exclusions and conditional use. The medicine is primarily indicated for use in postmenopausal women.

Absolute Contraindications

L'estrogel is contraindicated and must not be used in individuals with a history of certain serious conditions. These absolute exclusions include known, suspected, or a history of breast cancer or any estrogen-dependent neoplasia. Use is also prohibited in patients with active or a history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or myocardial infarction (MI). Further contraindications include undiagnosed abnormal genital bleeding, known liver impairment or disease, and known thrombophilic disorders.

Conditional Use and Age Restrictions

For women with an intact uterus, the official label requires that L'estrogel be used with a co-administered progestogen to mitigate the risk of endometrial changes. Use is formally contraindicated during pregnancy and lactation. The medicine is not established or not indicated for use in the pediatric population. Special consideration is required for women aged 65 and older, for whom clinical experience is limited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The estradiol in L'estrogel is partially metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. This metabolic pathway is the main basis for potential drug interactions.

Metabolically-Based Interactions

Interaction Mechanism Interacting Substances (Examples) Potential Result
CYP3A4 Inducers Phenobarbital, Carbamazepine, Rifampin, St. John's Wort preparations Reduced plasma estrogen concentrations, potentially leading to a decrease in therapeutic effects and/or changes in the uterine bleeding profile.
CYP3A4 Inhibitors Erythromycin, Clarithromycin, Ketoconazole, Itraconazole, Ritonavir, Grapefruit juice Increased plasma estrogen concentrations, potentially resulting in an increased risk of side effects.

Procedural and Other Constraints

  • Topical Application: To ensure proper absorption and maintain consistent systemic estrogen concentrations, the application site should not be washed for at least one hour after the gel has been applied. Washing the site too soon may reduce the absorbed dose.
  • Flammability: L'estrogel is an alcohol-based gel and is flammable. Fire, flame, or smoking should be avoided until the gel has completely dried on the skin.

Note: Formal clinical drug interaction studies have not been conducted with L'estrogel. The interaction information provided is based on the known metabolism of estrogens and general drug metabolism principles.

Mechanism of Action

L'estrogel delivers 17beta-estradiol, a ligand and agonist for the classical nuclear estrogen receptors, Estrogen Receptor Alpha (ERalpha) and Estrogen Receptor Beta (ERbeta), which are distributed across numerous tissues including the reproductive tract, bone, and central nervous system. Following transdermal absorption and distribution, estradiol traverses the cell membrane and binds to these intracellular receptors.

Upon ligand binding, the receptor-ligand complex undergoes dimerization and translocates to the cell nucleus. In the nucleus, the complex functions as a transcription factor, primarily by binding directly to Estrogen Response Elements (EREs) within the promoter regions of target genes, or indirectly via protein-protein interactions with other transcription factors like SP-1 or AP-1. This genomic pathway modulates the transcription rate of specific genes, resulting in altered synthesis of downstream proteins.

Separately, estradiol also engages in rapid, non-genomic signaling by activating membrane-associated estrogen receptors and initiating cytoplasmic signaling cascades, including the MAPK and PI3K/AKT pathways. System-level physiological consequences include the modulation of pituitary gonadotropin secretion via negative feedback, specifically reducing circulating levels of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), and the homeostatic regulation of processes in target organs.

Dosage and Administration Information

L'estrogel is administered via the transdermal route, meaning the medicine is applied topically to the skin. The therapy is delivered as a clear hydroalcoholic gel using a metered-dose pump, which ensures accurate delivery of the prescribed dose. Before the initial use, the pump must be primed by fully depressing it three to five times, with the dispensed gel discarded, to ensure consistency in subsequent doses.


Dosing recommendations may vary. The single approved dose is 1.25 g of gel (equaling 0.75 mg estradiol) delivered by one pump depression once daily. In some instances, the usual starting dose is 2.5 g of gel (two pumps), and this may be adjusted up to a maximum daily dose of 5 g (four pumps) if required.


The gel must be applied once daily to a clean, dry skin area, such as the entire arm from wrist to shoulder or the arms, shoulders, and/or inner thighs. It must be allowed to dry for 2 to 5 minutes before dressing. A critical procedural constraint is to avoid applying the gel on or near the breasts and to avoid contact with others at the application site for at least one hour to prevent unintended transfer of the medicine.

For all patients with an intact uterus, the estrogen therapy is prescribed with a required progestogen co-administered for at least 12 days of each treatment cycle. Clinical standards dictate that treatment be maintained at the lowest effective dose for the shortest duration consistent with treatment goals.

Recent Clinical Evidence

Research evidence / Overview of studies for L'estrogel

The research base for L'estrogel (Estradiol Transdermal Gel) consists primarily of Randomized Controlled Trials (RCTs) and systematic reviews that explored how the systemic delivery of estradiol through the skin was associated with changes in symptoms and biomarkers related to estrogen deficiency. These studies were conducted to gather evidence aligned with official regulatory standards.


Evidence for Vasomotor Symptoms (Hot Flashes and Night Sweats)

This section summarizes the structure of Randomized Controlled Trials (RCTs) and systematic reviews that examined the gel's effect on the frequency and severity of moderate to severe hot flashes and night sweats in postmenopausal women.

Research has focused on women experiencing conditions characterized by fluctuating or episodic manifestations, specifically the acute discomfort of hot flashes and night sweats. The findings describe patterns observed in the studies: specifically, research reports on measurements taken during the study period related to the daily number and intensity of these episodic symptoms. Studies report how symptoms evolved in the observed populations compared to control groups, contributing to the broader evidence landscape for systemic estrogen therapy.

The results apply only to the populations studied, and it remains uncertain how these findings translate to broader or different groups. Follow-up durations were limited in many of the key trials, meaning that data for certain groups remain insufficient, and long-term effects on the durability of symptom relief are not fully established.


Evidence for Vulvar and Vaginal Atrophy Symptoms

This part covers the research, including RCTs, that investigated the gel's systemic impact on subjective symptoms (like dryness and painful intercourse) and objective biological markers of atrophy in vulvar and vaginal tissues.

Studies explored outcomes related to physical discomfort, such as vaginal dryness, burning, and painful intercourse (dyspareunia). Studies reported measurements of changes in the patient-reported scores for the most bothersome symptoms related to local atrophy. Reported measurements included shifts toward values associated with premenopausal status in objective markers like the Vaginal Maturation Index (VMI) and vaginal pH. Findings were consistent with the established scientific understanding of how systemic estrogen replacement interacts with estrogen-responsive tissues.


Evidence for Outcomes Related to Postmenopausal Osteoporosis

This summary reviews the structure of evidence, including long-term observational studies and Bone Mineral Density (BMD) trials, used to assess the role of systemic estradiol therapy in skeletal health in women at risk of fracture.

Systemic estradiol has been studied for outcomes related to postmenopausal osteoporosis in women at significant fracture risk. Findings indicate patterns related to the maintenance or increase of BMD. In the systemic estrogen class, data show patterns associated with lower fracture incidence. This evidence contributes to understanding overall bone mineral density patterns, but data for certain groups with pre-existing complex conditions remain insufficient.


Research Gaps and What Remains Uncertain

This final section synthesizes the major limitations and uncertainties noted in the official evidence base. For instance, comparative evidence is lacking between the transdermal gel formulation and newer or differing systemic or local estrogen therapies. Subgroup findings are uncertain, as there is limited information on how the gel may be associated with outcomes in women with specific underlying conditions or complex health profiles.

Key Studies & References

  1. Menopause: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about L'estrogel (FAQ)

Q: How quickly does L'estrogel start to work for hot flashes?

Clinical trials for L'estrogel have measured its effectiveness in reducing the frequency and severity of hot flashes and night sweats. Evidence indicates that statistically significant results can be demonstrated in study populations within the first four to twelve weeks of treatment.

Q: What if I forget to apply L'estrogel sometimes?

If a dose is missed, official regulatory guidance generally recommends applying the dose only if the next scheduled dose is more than 12 hours away. If the next application time is less than 12 hours away, the general guidance is to avoid applying the missed dose and resume the usual schedule, rather than applying two doses at once.

Q: Can L'estrogel cause weight gain?

Official drug labeling lists 'weight changes' or 'weight gain' as an adverse reaction that has been reported by users. This is classified among the less common side effects observed in regulatory data.

Q: Can I use other lotions or creams on the same skin area as L'estrogel?

Official labeling advises against using products like sunscreen or moisturizer on the application site for a specified period after applying the gel. This constraint is in place to help ensure the correct amount of medicine is absorbed into the bloodstream. It is important to review the use of other topical products with a healthcare professional.

Q: Is L'estrogel safe for women who have had a hysterectomy?

L'estrogel is indicated for use in postmenopausal women. Regulatory guidance requires that women with an intact uterus co-administer a progestin to mitigate the risk of changes to the uterine lining. Women who have had a hysterectomy do not have this same requirement for co-administration of a progestin.

Q: Does L'estrogel affect mood or cause emotional changes?

Adverse reactions reported in regulatory data include nervous system effects such as headache and dizziness. While the official list of common side effects may not explicitly name 'mood' or 'emotional changes,' any mental or emotional shifts outside the expected range of reactions are typically reviewed with a healthcare provider.

Q: Is L'estrogel safe to use long-term?

Official regulatory guidance states that all estrogen therapy should be maintained at the lowest effective dose for the shortest duration consistent with treatment goals. Furthermore, long-term use has been officially associated with documented serious risks, including an increased risk of breast cancer and blood clots.

Q: Can sun exposure affect how L'estrogel works?

Official labeling warns that the drug may cause dark patches of skin on the face, a condition known as melasma. Regulatory labeling suggests avoiding unnecessary exposure to the sun, sunlamps, and tanning beds, and using sunscreen and protective clothing to help manage this.

Q: Is L'estrogel meant for short-term or long-term symptom management?

Regulatory documents explicitly state that estrogen therapy should be used at the lowest effective dose for the shortest duration necessary to achieve the treatment goals. This reflects the medical consensus to manage symptoms while minimizing exposure time.

Q: Why is the application site important for L'estrogel absorption?

The gel is a transdermal formulation, meaning the active hormone must be absorbed through the skin's barrier. The specific areas recommended for application, such as the arm from the wrist to the shoulder, are necessary to ensure the gel covers a large enough area to achieve consistent and correct systemic levels in the body.

Q: Does smoking affect the safety or effectiveness of L'estrogel?

Official labeling includes a warning that smoking during estrogen therapy is associated with increased risk of developing serious side effects, such as heart disease and blood clots, associated with estrogen use.

Q: Does L'estrogel have a strong smell or odor?

Regulatory documents describe L'estrogel as a clear, colorless hydroalcoholic gel. The formulation is officially noted to be odorless when it has dried completely on the skin.

Q: Is it normal to feel a tingling sensation where I apply the gel?

Adverse reactions officially reported at the application site include common skin issues like irritation, itching, and rash. Any localized skin sensations outside the typical range of effects are generally reviewed with a healthcare provider.

Q: How long do most patients typically stay on L'estrogel?

Official recommendations state that treatment should be for the shortest duration possible, consistent with individual treatment goals. Use of the therapy is typically reviewed periodically by a healthcare professional to assess continued necessity.

Q: What happens if I stop using L'estrogel suddenly?

Abrupt discontinuation of the drug may lead to the recurrence of the menopausal symptoms that the medication was prescribed to treat. If treatment discontinuation is being considered, it is typically discussed with the prescriber.

Q: Does L'estrogel affect blood pressure?

Regulatory warnings state that estrogen therapy may potentially raise blood pressure or worsen already existing high blood pressure. Regular blood pressure monitoring is commonly part of the care for patients using this medication.

Q: What happens if I apply too much of the gel?

Symptoms that may suggest an overdose, as reported in regulatory information, include side effects such as nausea, vomiting, breast tenderness or pain, abdominal discomfort, fatigue, drowsiness, and vaginal bleeding.

Q: Can I go swimming or take a shower soon after applying L'estrogel?

Official instructions advise against washing the application site, including bathing, showering, or swimming, right after applying the gel. Pharmacokinetic studies show that washing the site, even one hour later, can result in a reduced absorbed dose, potentially affecting efficacy.

Q: Is L'estrogel prescribed for uses other than treating menopausal symptoms?

The specific gel formulation is officially indicated for the treatment of moderate to severe hot flashes (vasomotor symptoms) and moderate to severe symptoms of vulvar and vaginal atrophy, all related to menopause.

Q: Does L'estrogel need to be refrigerated?

No, regulatory documents require the gel to be stored at a controlled room temperature, typically ranging from 15 C to 30 C (59 F to 86 F). It must be protected from freezing, excessive heat, and direct light.

Q: Can I use L'estrogel if I have sensitive skin?

Regulatory data lists application site irritation, itching (pruritus), and rash as adverse reactions. The gel is also contraindicated, or prohibited, for individuals with a known allergy or hypersensitivity to the drug or any of its components.

Q: What is the purpose of the alcohol in the gel formulation?

The formulation is hydroalcoholic. The alcohol in the gel serves two primary functions: it helps to dissolve the active ingredient (estradiol) and assists in the transport of the hormone across the skin barrier to allow for systemic absorption. It also enables the quick-drying characteristic of the gel.

Q: Does L'estrogel affect cholesterol levels?

Official warnings mention that estrogen therapy has the potential to cause the severe elevation of blood triglycerides (a type of fat in the blood) in women who already have high levels. Monitoring of blood lipid profiles is commonly performed for patients using estrogen therapy.

Q: Are there any official reports of serious allergic reactions to L'estrogel?

Yes, official regulatory documents state that the product must not be used by women with a known anaphylactic reaction, angioedema, or hypersensitivity to the gel or its components, which implies documented cases of serious allergic reactions have occurred.

Q: What is the typical time frame for expected results mentioned in research?

Clinical studies on vasomotor symptoms (hot flashes) specifically demonstrated statistically significant improvements in both the frequency and severity of symptoms by the 4-week and 12-week marks of treatment.

How should L'estrogel be stored and disposed of?

Storing and Disposing of Estradiol Gel (L'estrogel)

Official regulatory documents require Estradiol gel to be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage must ensure the product is protected from freezing, excessive heat, moisture, and direct light.

Since the hydroalcoholic gel is flammable, the container must be kept tightly closed and stored away from fire, flame, or heat. For child safety, the medicine must be kept out of the reach of children.

Disposal instructions mandate that the unused gel from the pump's initial priming must be discarded by rinsing it down the sink or placing it in household trash. Once the specified number of doses has been delivered, the used pump dispenser must be thrown away.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of L'estrogel found in:

A-Z Index: